Search

Your search keyword '"Cmelak A"' showing total 748 results
Start Over Author "Cmelak A"
748 results on '"Cmelak A"'

352. 8519 A phase 2, randomized trial (CONCERT-1) of chemoradiotherapy with or without panitumumab in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Interim pooled safety analysis

Author

Fortin, A., primary, Cmelak, A., additional, Mesía, R., additional, Minn, H., additional, Chan, A.T.C., additional, Yunes, A.C., additional, Merlano, M.C., additional, Singh, S., additional, Smitt, M., additional, and Henke, M., additional

Published
2009
Full Text
View/download PDF

353. Evolution of clinical trials in head and neck cancer

Author

Yang, Eddy S., primary, Murphy, Barbara M., additional, Chung, Christine H., additional, Netterville, James L., additional, Burkey, Brian B., additional, Gilbert, Jill, additional, Yarbrough, Wendell G., additional, Sinard, Robert, additional, and Cmelak, Anthony J., additional

Published
2009
Full Text
View/download PDF

357. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: A tool to assess symptom burden in patients treated with chemoradiation

Author

Murphy, Barbara A., primary, Dietrich, Mary S., additional, Wells, Nancy, additional, Dwyer, Kathleen, additional, Ridner, Sheila H., additional, Silver, Heidi J., additional, Gilbert, Jill, additional, Chung, Christine H., additional, Cmelak, Anthony, additional, Burkey, Brian, additional, Yarbrough, Wendell G., additional, Sinard, Robert, additional, and Netterville, James, additional

Published
2009
Full Text
View/download PDF

359. Hypothyroidism as a consequence of intensity-modulated radiation therapy (IMRT) with concurrent taxane-based chemotherapy for locally-advanced head and neck cancer (LAHNC)

Author

Diaz, R., primary, Jaboin, J. J., additional, Stinson, S., additional, Gilbert, J., additional, Chung, C. H., additional, Murphy, B. A., additional, Burkey, B., additional, Netterville, J., additional, Yarbrough, W. G., additional, Murphy, P. B., additional, and Cmelak, A. J., additional

Published
2008
Full Text
View/download PDF

365. 8519 A phase 2, randomized trial (CONCERT-1) of chemoradiotherapy with or without panitumumab in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Interim pooled safety analysis

Author

A.C. Yunes, H. Minn, M.C. Merlano, A. Fortin, R. Mesía, M. Henke, A. Cmelak, A.T.C. Chan, S. Singh, and M. Smitt

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, law.invention, Unresected, Randomized controlled trial, law, Interim, Internal medicine, medicine, Panitumumab, Basal cell, In patient, Head and neck, business, Chemoradiotherapy, medicine.drug
Published
2009
Full Text
View/download PDF

368. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer

Author

Posner, Marshall R., primary, Hershock, Diane M., additional, Blajman, Cesar R., additional, Mickiewicz, Elizabeth, additional, Winquist, Eric, additional, Gorbounova, Vera, additional, Tjulandin, Sergei, additional, Shin, Dong M., additional, Cullen, Kevin, additional, Ervin, Thomas J., additional, Murphy, Barbara A., additional, Raez, Luis E., additional, Cohen, Roger B., additional, Spaulding, Monica, additional, Tishler, Roy B., additional, Roth, Berta, additional, Viroglio, Rosana del Carmen, additional, Venkatesan, Varagur, additional, Romanov, Ilya, additional, Agarwala, Sanjiv, additional, Harter, K. William, additional, Dugan, Matthew, additional, Cmelak, Anthony, additional, Markoe, Arnold M., additional, Read, Paul W., additional, Steinbrenner, Lynn, additional, Colevas, A. Dimitrios, additional, Norris, Charles M., additional, and Haddad, Robert I., additional

Published
2007
Full Text
View/download PDF

373. A Phase II Multi-institutional Trial of Chemoradiation Using Weekly Docetaxel and Erythropoietin for High-Risk Postoperative Head and Neck Cancer Patients

Author

Willey, Christopher D., primary, Murphy, Barbara A., additional, Netterville, James L., additional, Burkey, Brian B., additional, Shyr, Yu, additional, Shakhtour, Bashar, additional, Kish, Bonnie, additional, Raben, David, additional, Chen, Changhu, additional, Song, John I., additional, Kane, Madeleine A., additional, and Cmelak, Anthony J., additional

Published
2007
Full Text
View/download PDF

378. 25

Author

Cooper, J.S., primary, Pajak, T.F., additional, Forastiere, A.A., additional, Jacobs, J., additional, Campbell, B., additional, Saxman, S., additional, Kish, J., additional, Cmelak, A., additional, Kim, H., additional, and Fu, K., additional

Published
2006
Full Text
View/download PDF

379. Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas

Author

Chung, Christine H., primary, Ely, Kim, additional, McGavran, Loris, additional, Varella-Garcia, Marileila, additional, Parker, Joel, additional, Parker, Natalie, additional, Jarrett, Carolyn, additional, Carter, Jesse, additional, Murphy, Barbara A., additional, Netterville, James, additional, Burkey, Brian B., additional, Sinard, Robert, additional, Cmelak, Anthony, additional, Levy, Shawn, additional, Yarbrough, Wendell G., additional, Slebos, Robbert J.C., additional, and Hirsch, Fred R., additional

Published
2006
Full Text
View/download PDF

380. Hypothyroidism as a consequence of intensity-modulated radiation therapy (IMRT) with concurrent taxane-based chemotherapy for locally-advanced head and neck cancer (LAHNC)

Author

James L. Netterville, S. Stinson, Roberto Diaz, Barbara A. Murphy, Patrick Murphy, Anthony J. Cmelak, Wendell G. Yarbrough, Brian B. Burkey, Jerry J. Jaboin, Christine H. Chung, and Jill Gilbert

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Retrospective review, Chemotherapy, Taxane, business.industry, medicine.medical_treatment, Head and neck cancer, Locally advanced, Intensity-modulated radiation therapy, medicine.disease, humanities, Internal medicine, medicine, Intensity modulated radiotherapy, business
Abstract

6048 Background: We conducted a retrospective review of 129 consecutively-treated locally advanced head and neck cancer (LAHNC) patients treated with intensity modulated radiotherapy (IMRT)/chemoth...

Published
2008
Full Text
View/download PDF

381. E2399: Correlation of objective and self report measures of swallowing function after concurrent chemoradiation (CCR) for head and neck cancer (HNC)

Author

Anthony J. Cmelak, Mary S. Dietrich, Barbara Burtness, Barbara A. Murphy, and Arlene A. Forastiere

Subjects
Oncology, Cancer Research, medicine.medical_specialty, integumentary system, business.industry, digestive, oral, and skin physiology, fungi, Gold standard, Head and neck cancer, Concurrent chemoradiation, Function preservation, medicine.disease, Correlation, Swallowing, Self-report study, Internal medicine, Medicine, business
Abstract

6022 Background: We conducted a correlative study for E2399, a function preservation trial, to assess the acute and long-term effects of CCR on swallowing and the relationship of “gold standard” ob...

Published
2008
Full Text
View/download PDF

382. Gene expression profile of pemetrexed and oxaliplatin response in a phase II induction trial in locally advanced head and neck squamous cell carcinoma

Author

Wendell G. Yarbrough, James L. Netterville, Barbara A. Murphy, Robert J. Sinard, Anthony J. Cmelak, Joel S. Parker, Jill Gilbert, Christine H. Chung, Joseph M. Aulino, and Brian B. Burkey

Subjects
Oncology, Larynx, Cancer Research, medicine.medical_specialty, business.industry, DNA repair, medicine.disease, Head and neck squamous-cell carcinoma, Oxaliplatin, stomatognathic diseases, Regimen, medicine.anatomical_structure, Pemetrexed, Internal medicine, Significance analysis of microarrays, otorhinolaryngologic diseases, Medicine, Biomarker (medicine), business, medicine.drug
Abstract

6039 Background: To assess the efficacy and identify a biomarker of response, a phase II trial of pemetrexed (PT) and oxaliplatin (OX) as an induction regimen in locally advanced head and neck squamous cell carcinoma (HNSCC) was conducted. We hypothesized that the tumors with increased DNA repair and folate biosynthesis capacities would have resistance to the regimen. Methods: Patients (pts) were given PT 500 mg/m2 and OX 85 mg/m2 Q 2 weeks for 4 cycles. Response was assessed at the end of treatment by CT scan. Frozen and formalin-fixed paraffin-embedded tumors were collected for DNA microarray analysis. The gene expression data were queried using significance analysis of microarrays (SAM) for comparison of stable disease (SD) versus partial response (PR). Results: 15 pts have been enrolled (Male/female: 14/1, Median age: 57.3). ECOG PS: 0 (6), 1 (8) and 2 (1). Primary sites: oropharynx (5), oral cavity (6), larynx (2), hypopharynx (1) and unknown primary (1). Fourteen of the 15 pts were evaluable for res...

Published
2008
Full Text
View/download PDF

383. Head and neck cancer (HNC), depression, and genetic polymorphism

Author

Christine H. Chung, Anthony J. Cmelak, Wendell G. Yarbrough, Mary S. Dietrich, Barbara A. Murphy, Kirsten L. Haman, N. J. Muldowney, Randy D. Blakely, Jill Gilbert, and M. Pham

Subjects
Oncology, Cancer Research, medicine.medical_specialty, education.field_of_study, business.industry, Internal medicine, Head and neck cancer, Population, medicine, medicine.disease, education, business
Abstract

6017 Background: The prevalence of depression in the cancer population exceeds that of the general population, with HNC patients having among the highest rates. Whereas genetic polymorphism (short/...

Published
2008
Full Text
View/download PDF

384. Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-κB Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma

Author

Chung, Christine H., primary, Parker, Joel S., additional, Ely, Kim, additional, Carter, Jesse, additional, Yi, Yajun, additional, Murphy, Barbara A., additional, Ang, K. Kian, additional, El-Naggar, Adel K., additional, Zanation, Adam M., additional, Cmelak, Anthony J., additional, Levy, Shawn, additional, Slebos, Robbert J., additional, and Yarbrough, Wendell G., additional

Published
2006
Full Text
View/download PDF

387. Esthesioneuroblastoma

Author

Murphy, Barbara A., primary, Aulino, Joseph M., additional, Chung, Christine H., additional, Ely, Kim, additional, Sinard, Robert, additional, and Cmelak, Anthony, additional

Published
2006
Full Text
View/download PDF

388. Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell Carcinoma

Author

Slebos, Robbert J.C., primary, Yi, Yajun, additional, Ely, Kim, additional, Carter, Jesse, additional, Evjen, Amy, additional, Zhang, Xueqiong, additional, Shyr, Yu, additional, Murphy, Barbara M., additional, Cmelak, Anthony J., additional, Burkey, Brian B., additional, Netterville, James L., additional, Levy, Shawn, additional, Yarbrough, Wendell G., additional, and Chung, Christine H., additional

Published
2006
Full Text
View/download PDF

395. Supradose Intra-Arterial Cisplatin and Concurrent Radiation Therapy for the Treatment of Stage IV Head and Neck Squamous Cell Carcinoma Is Feasible and Efficacious in a Multi-Institutional Setting: Results of Radiation Therapy Oncology Group Trial 9615

Author

Robbins, K. Thomas, primary, Kumar, Parvesh, additional, Harris, Jonathan, additional, McCulloch, Timothy, additional, Cmelak, Anthony, additional, Sofferman, Robert, additional, Levine, Paul, additional, Weisman, Robert, additional, Wilson, William, additional, Weymuller, Ernest, additional, and Fu, Karen, additional

Published
2005
Full Text
View/download PDF

396. Intensity-Modulated Radiation Therapy (IMRT) With Concurrent Taxane-Based Chemotherapy for Locally-Advanced Head and Neck Cancer (LAHNC): Toxicities and Efficacy

Author

M. Beach, Anthony J. Cmelak, S.W. Thorpe, Patrick Murphy, W. Kirby, Barbara A. Murphy, B. Shakhtour, Christine H. Chung, Brian B. Burkey, and Roberto Diaz

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Radiation, Taxane, business.industry, medicine.medical_treatment, Head and neck cancer, Locally advanced, Intensity-modulated radiation therapy, medicine.disease, Radiation therapy, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2007
Full Text
View/download PDF

397. Phase II trial of irinotecan (Ir) plus cisplatin (CDDP) in patients with recurrent or metastatic squamous carcinoma of the head and neck (SCCHN)

Author

Jill Gilbert, Chung Ch, Brian B. Burkey, Robert J. Sinard, V. Paty, B. Murphy, James L. Netterville, T. Hudson, Anthony J. Cmelak, and W. Yarborough

Subjects
Oncology, Cisplatin, Cancer Research, Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Cancer, medicine.disease, Gastroenterology, Squamous carcinoma, Irinotecan, Internal medicine, Toxicity, Medicine, In patient, Dose Reduced, business, medicine.drug
Abstract

6041 Background: Prognosis for recurrent or metastatic SCCHN patients remains poor with median survivals of 6–9 months. Therapies targeting this group are needed. We conducted a single arm Phase II trial of Ir plus CDDP in patients with recurrent or metastatic SCCHN. The goal of this trial was to evaluate the efficacy and toxicity of this combination in advanced SCCHN. Methods: Eligible patients had incurable SCCHN, an ECOG PS of 0–2 and were chemonaive (no prior chemotherapy or chemotherapy for primary disease at least 6 months prior to study entry). A two-stage accrual design (Simon) was used. Irinotecan 65 mg/m2 and CDDP 30 mg/m2 were administered weekly for 4 weeks, followed by a 2 week rest for a 6 week cycle. Due to GI toxicity and neutropenia, the Ir was decreased to 50 mg/m2 with CDDP 30 mg/m2. Response assessment was made after every cycle using WHO criteria. The primary endpoint was response rate. Results: Forty patients were enrolled (male: 33, female:7). Median age was 58 (33–79). Forty and 32 patients were evaluable for toxicity and response, respectively. Reasons for unevaluable: 7 without at least 1 full cycle of therapy; 1 patient with incomplete records. Overall response rate was 34% (11/32 PR) with 18% SD (6/32). Median progression free survival was 2.6 months. The median overall survival was 8.2 months. Toxicity was substantial at Ir 65 mg/m2 with a rate of Grade (G) 3 or 4 toxicity of 82% compared to 56% at Ir 50 mg/m2. For both dose levels, G 3 or 4 nausea and vomiting (23%), diarrhea (15%) and neutropenia (35%) were the most common toxicities. Conclusions: The combination of irinotecan and cisplatin is active in a poor prognosis group of patients. Toxicity of irinotecan at 65 mg/m2 with CDDP 30 mg/m2 is substantial. Irinotecan 50 mg/m2 and CDDP 30 mg/m2 is tolerable and provides a 34% response rate. No significant financial relationships to disclose.

Published
2007
Full Text
View/download PDF

398. Single Agent Irinotecan for the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)

Author

Anthony J. Cmelak, Barbara A. Murphy, James L. Netterville, Dang T, Chung Ch, Yu Shyr, Jill Gilbert, Brian B. Burkey, and Ikpeazu E

Subjects
Oncology, medicine.medical_specialty, Pathology, education.field_of_study, Chemotherapy, business.industry, medicine.medical_treatment, Head and neck cancer, Population, Cancer, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, lcsh:RC254-282, Squamous carcinoma, Irinotecan, Internal medicine, Toxicity, Cohort, Medicine, business, education, medicine.drug
Abstract

Background Patients with recurrent or metastatic head and neck cancer (HNC) have a poor response and survival with currently available chemotherapy agents. Thus new agents are needed. We report the results of a phase II trial of irinotecan in patients with metastatic or recurrent HNC. Patients and Methods Chemonaive patients were treated with irinotecan 125 mg/m2 on a weekly schedule for four weeks, followed by a two week rest. However, due to excessive toxicity, the dose and schedule of irinotecan was changed to 75 mg/m2 on days 1 and 8 of a 21 day cycle. All previously treated patients received 75 mg/m2 on days 1 and 8 of a 21 day cycle. Results Forty-nine patients were enrolled on study. The response rate was 20% in the chemonaive patients treated at the 125 mg/m2 dose. The response rate decreased to 12.5% at the 75 mg/m2 dose. In the previously treated cohort, the response rate was 20%. Median survival for the chemonaive and previously treated cohorts were 6.7 months and 5.0 months, respectively. Conclusions Irinotecan has modest activity in chemonaive and previously treated HNC, thus it merits further study in this advanced disease population.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results